Tagged: QBI Coronavirus Research Group

How targeting a key SARS-CoV-2 enzyme could lead to an antiviral drug

Fri Jul 10, 2020

Elisabeth Fall

James Fraser, PhD

The chemical fragments could bind to and disable an enzyme that helps the virus replicate.

SARS-CoV-2 may spur growth of molecular "railways" out of infected cells, School scientists show

Thu Jul 2, 2020

NIAID/NIH

SARS-CoV-2 viral particles and human cells

UCSF-led collaboration uncovers new avenues for COVID-19 drug discovery

COVID-19 relies on cell’s ‘master regulators’ for survival

Tue Jun 30, 2020

QBI Coronavirus Research Group identifies drugs that block SARS-CoV-2 in the laboratory

Thu May 28, 2020

Krogan, Galonic Fujimori, Jura, Fraser, and Agard

Susan Merrell

Nevan Krogan, PhD (standing), leads a meeting of the QBI Coronavirus Research Group with fellow UCSF faculty members (seated from left) Danica Galonic Fujimori, PhD; Natalia Jura, PhD; James Fraser, PhD; and David Agard, PhD.

The QBI Coronavirus Research Group found six drugs that effectively beat back SARS-COV-2 in the laboratory.

UCSF team has discovered drugs that block coronavirus, paving way for 'a better drug sooner'

Thu May 7, 2020

QBI Coronavirus Research Group races toward a cure

Tue Mar 31, 2020

SARS-COV2 virus particles on human cells

NIH

SARS-COV2 virus particles (orange), which cause COVID-19, on human cells (blue).

The UCSF Quantitative Biosciences Institute has made headway identifying dozens of potential therapies for the COVID-19 outbreak.

Hunting for a cure for COVID-19: an insider’s story

Sat Mar 21, 2020

QBI’s director, Nevan Krogan, PhD, left, and Jacqueline Fabius, QBI's chief operating officer

The chief operating officer of the Quantitative Biosciences Institute (QBI) shares a view of the team's work on COVID-19.